Clinical and pathological disappearance of peritoneal dissemination in a patient with advanced gastric cancer receiving chemotherapy with S-1 and low-dose cisplatin

被引:4
|
作者
Akatsu Y. [1 ]
Saikawa Y. [1 ]
Kubota T. [1 ]
Yoshida M. [1 ]
Furukawa T. [1 ]
Otani Y. [1 ]
Kumai K. [2 ]
Kitajima M. [1 ]
机构
[1] Department of Surgery, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582
[2] Ctr. for Diagn./Therapeut. Endoscopy, Keio University School of Medicine, Tokyo
关键词
Cisplatin; Gastric cancer; Peritoneal dissemination; S-1;
D O I
10.1007/s10120-004-0281-8
中图分类号
学科分类号
摘要
A 54-year-old woman with severe abdominal distention suffered from massive ascites. Cytological examination revealed adenocareinoma cells, leading to a diagnosis of peritonitis carcinomatosa. Gastrointestinal fiberseopy (GIF) resulted in a histological diagnosis of type 4 advanced gastric cancer with signet-ring cell carcinoma. The clinical diagnosis was confirmed to be cT3(SE)cN1cM0cH0cP1, cStage IV gastric cancer, type 4, according to the Japanese classification of gastric carcinoma. The patient was treated with S-1 and low-dose cisplatin (CDDP) in order to alleviate the critical state of the disease. After the third cycle of the regimen, the clinical response of P1 was classified as a partial response (PR) according to the World Health Organization (WHO) criteria. The patient's appetite loss and abdominal discomfort were markedly alleviated. The patient experienced grade 2 leukocytopenia throughout the regimen. Surgery was performed. Ascites and peritoneal disseminated lesions were not observed, and cytological examination of the peritoneal washes was negative. Total gastrectomy with D1 lymph node dissection was performed, and the surgical diagnosis was sT3(SE)sN0sM0sH0sP0; sStage II Microscopically, viable cancer cells were found to be scattered throughout the subserosal-serosal layers in the resected stomach. All of the samples from lesions that were potentially cancers involving peritoneal dissemination were diagnosed as fibrous scar tissues without any viable cancer cells. The patient is alive without recurrence at 10 months after surgery and 14 months after the initial chemotherapy. Thus, systemic chemotherapy with S-1/low-dose CDDP achieved desirable control of peritoneal disseminated cells, as assessed microscopically, suggesting that the regimen may be an effective strategy for the treatment of advanced gastric cancer with peritonitis carcinomatosa.
引用
收藏
页码:128 / 133
页数:5
相关论文
共 50 条
  • [41] Low-dose docetaxel and cisplatin combination chemotherapy for stage II/III gastric cancer showing resistance to S-1 adjuvant chemotherapy: a phase I study
    Kunisaki, Chikara
    Ono, Hidetaka A.
    Hasegawa, Shinichi
    Oshima, Takashi
    Fujii, Shoichi
    Tokuhisa, Motohiko
    Izumisawa, Yusuke
    Takagawa, Ryo
    Kimura, Jun
    Kosaka, Takashi
    Makino, Hirochika
    Akiyama, Hirotoshi
    Endo, Itaru
    JOURNAL OF CHEMOTHERAPY, 2012, 24 (06) : 364 - 372
  • [42] Adjuvant S-1 Chemotherapy for Gastric Cancer and Peritoneal Wash
    John Spiliotis
    Odysseas Zoras
    World Journal of Surgery, 2011, 35 : 468 - 469
  • [43] Experimental study to evaluate the usefulness of S-1 in a model of peritoneal dissemination of gastric cancer
    Takuji Mori
    Yoshiyuki Fujiwara
    Masahiko Yano
    Shigeyuki Tamura
    Takushi Yasuda
    Shuji Takiguchi
    Morito Monden
    Gastric Cancer, 2003, 6 (Suppl 1) : 13 - 18
  • [44] S-1 adjuvant chemotherapy for advanced gastric cancer
    Kelsen, David
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (07): : 370 - 371
  • [45] Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer
    D. Takahari
    T. Hamaguchi
    K. Yoshimura
    H. Katai
    S. Ito
    N. Fuse
    T. Kinoshita
    H. Yasui
    M. Terashima
    M. Goto
    N. Tanigawa
    K. Shirao
    T. Sano
    M. Sasako
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 1423 - 1428
  • [46] Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer
    Takahari, D.
    Hamaguchi, T.
    Yoshimura, K.
    Katai, H.
    Ito, S.
    Fuse, N.
    Kinoshita, T.
    Yasui, H.
    Terashima, M.
    Goto, M.
    Tanigawa, N.
    Shirao, K.
    Sano, T.
    Sasako, M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) : 1423 - 1428
  • [47] Feasibility Study of Triplet Combination Chemotherapy of Paclitaxel, Cisplatin and S-1 for Advanced Gastric Cancer
    Fujitani, Kazumasa
    Hasegawa, Hiroko
    Hirao, Motohiro
    Kurokawa, Yukinori
    Tsujinaka, Toshimasa
    ANTICANCER RESEARCH, 2011, 31 (09) : 3085 - 3091
  • [48] A Phase I Study of Triplet Combination Chemotherapy of Paclitaxel, Cisplatin and S-1 in Patients with Advanced Gastric Cancer
    Kimura, Yutaka
    Yano, Hiroshi
    Imamura, Hiroshi
    Fujitani, Kazumasa
    Imano, Motohiro
    Tokunaga, Yukihiko
    Matsuoka, Masaki
    Kurokawa, Yukinori
    Shimokawa, Toshio
    Takiuchi, Hiroya
    Tsujinaka, Toshimasa
    Furukawa, Hiroshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (02) : 125 - 131
  • [49] Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer
    Tetsuji Terazawa
    Satoru Iwasa
    Atsuo Takashima
    Hitoshi Nishitani
    Yoshitaka Honma
    Ken Kato
    Tetsuya Hamaguchi
    Yasuhide Yamada
    Yasuhiro Shimada
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 2111 - 2116
  • [50] Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer
    Lee, KW
    Im, SA
    Yun, T
    Song, EK
    Na, II
    Shin, H
    Choi, IS
    Oh, DY
    Kim, JH
    Kim, DW
    Kim, TY
    Lee, JS
    Heo, DS
    Bang, YJ
    Kim, NK
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (12) : 720 - 726